Skip to main content
Premium Trial:

Request an Annual Quote

Ariana Pharma, Bio-Rad Team on Project to Study Chronic Hepatitis

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ariana Pharma today said it has joined a new partnership to improve the diagnosis and prognosis of chronic hepatitis.

Ariana will apply its Knowledge Extraction and Management (KEM) platform to discover new biomarkers that could lead to earlier diagnosis of fibrosis and the ability to predict drug-resistance, the Paris-based company said. It said that the KEM platform can combine genomic and proteomic data with patient characteristics to maximize the probability of an effective test.

Bio-Rad Laboratories is leading the three-year project, called Hepachronix, which also includes Beaujon Hospital in Paris, and the French National Institute of Health and Medical Research (INSERM).

In a statement, Ariana said that the goal of Hepachronix is to gain a better understanding of how liver fibrosis progresses from early, mild stage to debilitating diseases such as cirrhosis and hepatoma carcinoma. About 40 percent of hepatitis c virus patients do not respond to standard treatments, and Hepachronix seeks to develop biomarkers to characterize patient response to therapies.

France's Single Inter-Ministry Fund and the Ile de France region have provided funding for Hepachronix. Bio-Rad will market in vitro diagnostic reagents resulting from the collaboration, and the partners will share royalties from any sales, Ariana said.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.